The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Investors Count

1

Deal Terms

1

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Funding, Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Valuation & Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Revenue

1 Fundings

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest funding round was a Acquired Unit for on April 6, 2016.

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest post-money valuation is from April 2016.

Sign up for a free trial to see Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's valuations in April 2016 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

4/6/2016

Acquired Unit

$99M

0

FY undefined

3

Date

4/6/2016

Round

Acquired Unit

Amount

Investors

Valuation

$99M

Revenue

0

FY undefined

Sources

3

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Deal Terms

1 Deal Term

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's deal structure is available for 1 funding round, including their Acquired Unit from April 06, 2016.

Round

Acquired Unit

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

$99M

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired Unit

$99M

$99M

$99M

$99M

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Investors

1 Investors

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program has 1 investors. Gilead Sciences invested in Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's Acquired Unit funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

4/6/2016

4/6/2016

1
Acquired Unit

Corporation

California

First funding

4/6/2016

Last Funding

4/6/2016

Investor

Rounds

1
Acquired Unit

Board Seats

Type

Corporation

Location

California

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.